Triticum aestivum Linn. for COVID-19
Triticum aestivum Linn. has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
In Silico study of Wheatgrass constituents against Coronavirus COVID-19 Proteins., Center for Open Science, doi:10.31219/osf.io/kg7yx ,
<p>Due to the COVID-19 pandemic, the virus associated with SARS-CoV-2 has emerged as an unparalleled global health crisis, marked by its extreme lethality and contagion. While vaccines offer a critical defence, they alone cannot guarantee a healthy future. Thus, alongside vaccine production, the development of effective treatments is imperative. This study is driven by exploring the therapeutic capabilities of specific chemical constituents found in Wheatgrass (Triticum aestivum Linn.) that hold potential for treating COVID-19. Seven distinct chemical constituents from Wheatgrass—namely, Ascorbic acid (SWA00A), Rutin (SWA00B), Ferulic acid (SWA00C), quercetin (SWA00D), Luteolin (SWA00E), Apigenin (SWA00F), and Kaempferol (SWA00G)—were subjected to virtual screening.The focus of this investigation encompassed COVID-19 viral proteins: 6lu7-SARS-CoV-2 main protease, 6zsl-SARS-CoV-2 helicase, 6w9c-papain-like protease of SARS-CoV-2, and 6m71-RNA-dependent RNA polymerase. As reference points, established drugs used in COVID-19 treatment, including Remdesivir, Darunavir, Ralimetinib, Berzosertib, Alpha-interferon, Arabinol, Chloroquine phosphate, Indinavir, Lopinavir, Ritonavir, Plegylated alfa interferon, and 2-chloro-2-deoxy-D-glucose, were employed as standards. Leveraging the PyRx Virtual Screening tool, molecular docking analyses were executed.Rutin (SWA00B) showcased the most formidable binding affinity among the seven chemical constituents evaluated. This study's findings highlight the robust potential of Rutin, a component present in Wheatgrass, to inhibit key SARS-CoV-2 proteins. While Wheatgrass displays promising anti-SARS-CoV-2 properties, it's pivotal to underscore the necessity for further in-depth research to ascertain their efficacy within in vivo settings</p>
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.